1. Introduction
Joint pain is defined as discomfort or tenderness in one or more joints. Acute joint pain is any joint pain that is expected to resolve within 6–8 weeks; chronic pain persists beyond this window [
1].
Joint pain is common and usually felt in the hands, feet, hips, knees, or spine. The most common cause of chronic knee pain is degenerative osteoarthritis (OA) [
2]. Other etiologies of knee pain include rheumatoid arthritis, crystal and spondylo-arthropathies, post-traumatic pain, and persistent postsurgical pain [
3]. The pathogenesis of OA results from an interplay of biomechanical, inflammatory, and metabolic factors that contribute to cartilage damage, synovitis, and various subchondral bone abnormalities [
4,
5,
6,
7]. The underlying pain of this discomfort may be constant or intermittent, and the joint may sometimes feel stiff, sore, or irritated. Joint pain can impair joint function and limit a person’s ability to perform basic tasks. In severe cases, joint pain can also affect quality of life. Joint pain is also a common phenomenon in people who use or overuse a muscle repeatedly, suffer from depression, anxiety, or stress, or are overweight, among others [
8]. Age also influences joint stiffness and pain. Hence, after years of wear and tear, middle-aged and older adults are typically more prone to experience symptoms of joint-related pain or discomfort.
Treatment for joint pain should not only focus on reducing pain, but maintaining mobility and reducing disability as well [
8]. The most commonly used pharmacological treatment are: acetaminophen (higher dosage can produce nephropathy and increased risk of gastrointestinal (GI) bleeding, in addition, it is contraindicated in patients with liver disease or alcohol use), nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclo-oxygenase-2 (COX-2) inhibitors (they have some contraindications like as peptic ulcer disease, GI bleed, renal disease, liver disease, and sensitivity to aspirin) [
9], the opioids (they have some side effects like as GI and sedation) [
10]. However, this type of treatment may improve symptoms, but not prevent the progression of the disease that causes the pain [
11].
A more recent, vastly investigated alternative to pharmacological treatments is the use of collagen-based food supplements. The hydrolyzed collagen is a form of collagen that is processed intensively to break up the large collagen molecules into smaller fragments to increase absorption. Hydrolyzed collagen and gelatin may be the same in terms of amino acid composition, but they possess different chemical properties. Collagen is a native protein molecule with a molecular weight of ~300 kDa [
12]. To produce hydrolyzed collagen, native collagen undergoes denaturation followed by a hydrolysis process, resulting in very low molecular mass (3–6 kDa) collagen peptides [
12].
Different processing and post-processing methods to make collagen hydrolyzate can yield vastly different products, creating different collagen peptide sequences and molecular weights. These differences can potentially impact biological function in terms of regulating joint inflammation and the effect on subchondral bone. Furthermore, lower molecular weight collagen peptides may be more easily absorbed in the small intestine, theoretically increasing the likelihood of being delivered to other areas in the body, including joints. The resistance of collagen peptides to hydrolysis and digestion is primarily based on amino acid composition. In that regard, peptides with the amino acid proline or hydroxyproline are not readily hydrolyzed or digested by the gastrointestinal system, which may allow them to be absorbed in the small intestine [
13,
14].
The food supplements containing collagen have been recognized as safe by the Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA) [
15,
16]. In addition, a 2017 meta-analysis of 69 clinical trials concluded that it is safe for use as a dietary supplement in humans to treat joint pain [
17].
Of the 28 types of collagens, type II is one of the most abundant, accounting for 50% of the cartilage protein in joints. Researchers observed that when hydrolyzed collagen is administered orally, it is absorbed in the intestine and stimulates chondrocytes to produce type II collagen [
18,
19]. Some researchers even suggest that type II collagen has the potential to repair or regenerate damaged collagen [
20]. In a 2006 study, 100 volunteers who experienced hip, shoulder, or knee pain associated with physical activity were given 10 g of hydrolyzed collagen daily for 12 weeks. As a result, 78% of participants reported reduced pain in the affected joint [
18]. Another study [
20] in patients with knee osteoarthritis found that those who ingested 10 g of hydrolyzed collagen per day had significantly less pain, as measured by a visual analogue pain scale (VAS), compared to placebo. In addition, there was an improvement in their score on the Western Ontario and McMaster Universities Arthritis Index (WOMAC). Pain improvement during physical activity is a measure used to assess pain reduction in the knee joint. This parameter was improved in participants in a randomized, double-blind clinical trial who had taken a formula based on hydrolyzed collagen compared to participants taking a placebo [
21].
Knee range of motion (ROM) is essential to daily function for normal active individuals. Interventions aimed at improving ROM have been shown to relieve joint stiffness, increase joint mobility, and maintain joint function [
21].
Various formulations of collagen-based products are currently available. However, it remains a challenge to continue to develop new formulations to check if there are improvements in efficacy with new products. In this sense, the primary aim of the present study was to evaluate the long-term effectiveness of a food supplement based on hydrolyzed collagen alongside other active ingredients on knee joint pain, knee range of motion, and quality of life questionnaires in a moderately active population. Therefore, we hypothesize that long-term intake of a collagen supplement together in combination with active ingredients, may improve knee pain and other quality of life parameters in moderately active subjects.
3. Results
3.1. Disposition of the Subjects
The following diagram (
Figure 2) shows subject flow from being recuiting until analyzed.
3.2. Baseline Characteristics of the Population
The individuals included in this study had a mean age of 35.1 ± 12.1 years. A total of 49.4% were men and 50.6% were women. The mean body weight of these individuals was 72.2 ± 13.5 kg and height 172 ± 10.7 cm, giving a mean BMI of 24.3 ± 2.7. Therefore, the BMI of the population studied was in the normal weight range.
After being randomized to the two treatment groups, there were no differences in age, weight, height, and BMI between the two groups. The distribution of males and females in each group was also the same.
Therefore, it can be concluded that the sample of individuals studied was homogeneous in terms of their demographic characteristics (
Table 1).
3.3. Measurement of the VAS Pain Scale 30 min After Waking Up
It was observed that the evolution of pain at 40 days showed a significant reduction (
p < 0.05) in the group taking IF, while the reduction in the group taking the placebo was not significant. Furthermore, the difference between the two groups was almost significant (
p = 0.082), indicating that treatment with IF tends to significantly reduce the pain felt upon waking up each morning, after 40 days of treatment (
Table 2).
Furthermore, from week 4 onwards, weekly differences very close to statistical significance were observed between the two treatment groups; the statistical significance was obtained at week 6 (result with *) with a clear reduction in pain in the group that received IF with respect to the group placebo (
Table 3). These results indicate that the administration of the collagen-based food supplement has an effect on the reduction of pain felt just after waking up in the morning.
3.4. Measurement of the VAS Pain Scale 3 h After the Physical Activity Performed
Table 4 shows the mean results of perceived pain 3 h after physical activity.
The mean weekly value of pain felt after 3 h of physical activity was calculated and compared with baseline (
Table 5). Each week, the difference from baseline was statistically significant (
p < 0.05) in the two treatment groups. The comparisons made between the groups each week showed no significant differences except for week 6, when, considering the time factor and the treatment factor, the IF group reduced pain significantly (
p < 0.05) with respect to the placebo.
3.5. KOOS Questionnaire Results for Knee Evaluation
Table 6 shows the mean and standard deviation of the domains of the KOOS questionnaire: pain, activities of daily living, functionality, sports and recreational activities, quality of life, and symptoms measured at the study visits.
For pain, an increase in this variable was observed over time, which implies an improvement in pain in both groups (IF and placebo) (
Table 6). Furthermore, when comparing the results of each visit with respect to the baseline (
Table 6), significant differences were obtained (
p < 0.05) for both the IF group and the placebo group. However, when comparing the groups, they did not differ significantly.
For daily activities, it is observed that in both treatment groups, the results increase as the study progresses. However, when comparing the results between each visit and the baseline visit (
Table 6), significant differences are obtained (
p < 0.05), but when comparing the two treatment groups, no differences are found between them.
For functionality, recreational activities, and sports, the results increase in both treatment groups (
Table 6). However, when comparing the results between each visit and the baseline visit, significant differences are obtained (
p < 0.05), but when comparing the two treatment groups, no differences are found between them (
Table 6).
The results obtained (
Table 6) for each of the dimensions measured in the KOOS questionnaire have shown a significant reduction in knee problems over time, in both treatment groups. The reduction in knee problems was greater in all dimensions in the group treated with IF, although only the dimension related to symptoms associated with knee problems (KOOS symptoms) showed significant differences (
p < 0.05) between the treatment groups.
3.6. WOMAC Osteoarthritis Scale
Differences were observed (
Table 7) in the functional capacity results between visit 2 and the initial visit. There were significant differences (
p < 0.05) as a function of time, and taking into account the time and treatment factor, showed an improvement in functional capacity in the group treated with IF with respect to the group treated with placebo.
The results showed a reduction in the score of each domain at visit 2 for the two treatment groups (
Table 7). The reduction was significant (
p < 0.05) in both groups, but it was greater for the IF-treated group in all the domains analyzed.
In the functional capacity domain, it was found that the improvement was significantly (p < 0.05) greater in the group treated with IF with respect to the placebo group.
3.7. SF-36 Health Questionnaire
The general health of the participants who took the placebo product worsened statistically significantly (
p < 0.05) during the study (
Table 8). This was not observed in the participants treated with the IF product. Furthermore, when comparing the general health results obtained for both groups, a significant difference (
p < 0.05) was obtained between the two treatments.
The following table shows that the quality of life of the individuals who took the collagen-based product improved significantly (p < 0.05) with respect to those who took a placebo, taking into account the time factor and the treatment factor.
3.8. Knee Range of Motion (ROM) by Goniometry
The participant performs a voluntary flexion of the leg to the maximum possible point or until pain is felt. The higher the ROM angle value, the greater the flexion. Therefore, an increase in the ROM angle indicates improvement (
Table 9).
On day 40 of the study, there was a significant (p < 0.05) decrease in ROM angle in the placebo-treated group, thereby indicating a decrease in knee flexion amplitude and thus a worsening of the participants’ condition. IF-treated individuals slightly increased the ROM angle, but this increase was not significant. However, when the two treatment groups were compared, a trend towards statistical significance (p = 0.072) of the difference was obtained. It could be concluded that the intake of the collagen-based food supplement prevents the progression of the worsening of the condition suffered by the affected knee.
4. Discussion
The main objective of this study was to evaluate the effect of chronic supplementation with a food supplement based on hydrolyzed collagen and other active ingredients on knee joint pain in a moderately active population. The main findings of this study were an improvement in the WOMAC, KOOS, SF-36, and EVA questionnaires after the end of the IF supplementation period. This is in line with the hypothesis generated, where we established that chronic IF intake improved quality of life and pain parameters in moderately active subjects.
In the present study, analysis of the primary outcome measure, which was the proportion of subjects who experienced a reduction in pain as defined by a >30 mm decrease in VAS, (
Table 5) showed a significant decrease 30 min after standing up (
p = 0.022) and 3 h after exercise (
p = 0.019) in the IF-supplemented group (
Table 7). Our results are in line with those found in previous studies (controlled clinical trials), which have shown that patients with different osteoarthritic conditions can improve the subjective symptoms of arthritic conditions following the intake of 10 g daily of IF [
34,
35,
36,
37,
38].
In addition, we also found improvements in the WOMAC test after chronic IF supplementation. In line with these results, a similar study [
39] also found that hydrolyzed collagen supplementation improved WOMAC score in thirty subjects diagnosed with knee osteoarthritis. However, the main difference with this study is that we excluded patients with diagnosed osteoarthritis since our goal was to evaluate the effect of IF supplementation in the general population. Furthermore, when comparing our results with other studies, it’s important to highlight the fact that they evaluated the effect of the intake of collagen on joint problems simultaneously with non-steroidal analgesics, analgesics, antipyretics, corticosteroids, and this may introduce bias in the conclusions obtained [
18,
19,
20,
40]. Therefore, based on our results in the VAS and WOMAC tests, chronic supplementation with the IF can improve perceived pain in the active population.
On the other hand, we also found improvements in the score of KOOS after chronic IF supplementation. Some other authors [
26,
41] also found similar results, particularly a study published in 2023 [
42] saw a difference in the mentioned questionnaire in people who exercised 188 min per week. Physical exercise can reduce pain with collagen supplementation because it can increase blood flow and the supply of amino acids and bioactive peptides to the connective tissue (low vascularity) during exercise. The pain-mitigating exercise-moderating effects of collagen supplementation may be attributed to increased blood flow and delivery of bioactive amino acids and peptides to connective tissue during exercise, which is otherwise poorly vascularized [
43,
44].
No improvement in knee ROM is seen after the supplementation period, but this is nevertheless a positive result as it maintains anatomical functionality and prevents deterioration, as opposed to the placebo, which shows some loss of functionality in ROM. The analysis shows a tendency to change between groups, so we can interpret that in longer periods of time or larger samples, clearer differences could be observed. This shows that the normal course of the ROM (Placebo) would worsen with time [
18], so that the investigational product would have a positive effect even if there is no improvement. In previous studies, several researchers [
18,
34] also found similar results for functional assessments applying mobility and flexibility tests, but in this case, they also found no differences or trends of change between groups. This result is important as it may indicate that IF may help to slow the functional deterioration of the knee joint.
With respect to the subjective evaluation of the perceived quality of life by means of the SF-36 questionnaire, we can find that the participants supplemented with IF showed improvements in the questions referring to physical function, both when comparing the effect of the treatment over time and in the comparison with the placebo group. In the questions corresponding to other aspects of quality of life recorded by the questionnaire, no notable changes were found. These findings are in the same direction as those found by previous research [
29,
45] that also report improvements in perceived physical function. Therefore, it can be stated that treatment with the IF supplement for 6 weeks improves the quality of life related to physical activity.
With the results obtained, we can consider that the IF used in this study can contribute to reducing knee joint pain in moderately active and otherwise healthy people with chronic pain, improving some aspects of their quality of life and functionality. These results contribute to corroborating other research with collagen-based products.
This study has several strengths, including the use of a product with a high total collagen content and a rigorous, double-blind, randomized, placebo-controlled study design. The main statistical methods and analyses were robust, which is further confirmed by a sensitivity analysis. Additionally, the study population included healthy people with general joint pain, stiffness, and lack of mobility, rather than patients diagnosed with OA alone.
Limitations of the Study and Future Directions
Some important limitations of this study were the duration of 40 days and the inclusion criteria of mild-moderate pain (40 mm out of 100 on the VAS scale). Additional studies are needed to further evaluate the long-term effects of the test product consumption on biochemical markers of inflammation, joint collagen formation and destruction, to have a more robust understanding of the effects of collagen supplementation on the general discomfort of the joints.